Navigation Links
DURECT Announces Sale of 4,444,444 Shares of Common Stock, Raising Proceeds of $10 Million
Date:9/11/2009

CUPERTINO, Calif., Sept. 11 /PRNewswire-FirstCall/ -- -- DURECT Corporation (Nasdaq: DRRX) today reported that it has entered into a privately negotiated transaction to sell 4,444,444 primary shares of common stock to affiliates of Venrock at a price of $2.25 per share, raising net proceeds to DURECT of approximately $10 million. DURECT expects the financing to close on or about September 18, 2009, subject to customary closing conditions.

(Logo:http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A shelf registration statement relating to the shares of common stock to be issued in the offering has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting DURECT Corporation, 2 Results Way, Cupertino, CA 95014 or through the SEC's electronic data system called IDEA (formerly EDGAR) at www.sec.gov. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of shares of DURECT's common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil.

About Venrock

Venrock is a premier venture capital firm with offices in Palo Alto, New York, Cambridge, MA, and Israel. Originally established as the venture capital arm of the Rockefeller family, Venrock continues the eight-decade tradition of partnering with entrepreneurs to establish successful, enduring companies. Having invested $2.4 billion in 437 companies resulting in 124 IPOs over the past 40 years, Venrock's investment returns place it among the top tier venture capital firms that have achieved consistently superior performance. With a primary focus on technology, healthcare, and energy, portfolio companies have included Adify, Adnexus Therapeutics, Apple Computer, Centocor, Check Point Software, DoubleClick, Gilead Sciences, Idec Pharmaceuticals, Illumina, Intel, Millennium Pharmaceuticals, Sirna Therapeutics, StrataCom, and Vontu. For more information, please visit Venrock's website at www.venrock.com.

DURECT Forward-Looking Statement

The statements in this press release regarding the expected closing of this financing are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the potential that the financing described above does not close on the date anticipated or at all. Further information regarding these and other risks is included in DURECT's Form 10-Q dated August 4, 2009 under the heading "Risk Factors."


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
2. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
3. DURECT Corporation Announces Second Quarter 2009 Financial
4. DURECT to Present at the BMO Capital Markets Healthcare Conference
5. DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
6. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
7. DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call
8. DURECT to Participate in Cowen and Company Healthcare Conference
9. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
10. DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
11. DURECT Corporation to Participate in Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. ... gold in Rio. Under the care of Maximized Living doctors at the London ... unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published ... her enthusiasm for Botox and lip injections, which she underwent in order to feel ... Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is not ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic ... the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain ... mood optimization products to the store is just one more way Shamangelic Healing ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... nation’s productivity, stability, even security. Most importantly, employees are the single most important ... are American workers so unhappy? , Just under half of American workers are ...
(Date:4/29/2016)... ... 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd ... sunny skies, a light breeze and temperatures in the 60s. Over 400 runners, walkers ... and Walk and 1-mile walk were held to increase awareness about Lyme disease ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... BERLIN , April 29, 2016 ... world-leading glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years ... pharmaceutical and biotechnology industries. His last role was at ... Member of the Executive Board. Previously Dr. Zurlo held ...
(Date:4/28/2016)... , April 28, 2016 Research ... "Global Plastic Surgery Products Market 2016-2020" report to ... ) , The global plastic surgery products ... 9.47% during the period 2016-2020. , ,The growing adoption ... to the growth of the market. Lasers are used ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 ... of online consumer insights on healthcare, announced today that ... in their report Cool Vendor in Life Sciences, ... , April 15, 2016.  The report focuses on life-science- ... to gain insight from patients and doctors, confirm medication ...
Breaking Medicine Technology: